VNValery Valerievich Novochadov

Valery Valerievich Novochadov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valery Valerievich Novochadov has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Producting yeast biomass with high protein and manganese content during the cheese whey processing

    by K. S. Abbas, V. V. Novochadov, T. A. Antipova, M. I. Slozhenkina, К. С. Аббас, В. В. Новочадов, Т. А. Антипова, М. И. Сложенкина

    The increase in the volume of cheese production waste and need for yeast biomass for the fodder production and the food industry determined the relevance of this study. Its purpose was to test the possibility of simultaneous removal of lactose from the cheese whey and production of biomass if Kluyveromyces yeasts are stimulated with manganese ions. We cultured the yeast strains Kluyveromyces lactis Y-2037 and Kluyveromyces marxianus Y-2042 for 72 hours in cheese whey without and with the addition of 10, 25 or 50 mg/l of manganese ions as sulfate salts. The final medium and biomass were separated. The analysis of the medium included the determination of lactose, ethanol, protein, and manganese content; the analysis of the biomass included protein and manganese measuring. Statistical processing of the obtained results was carried out. Fermentation of whey resulted in the processing of up to 90 % lactose to form up to 20 g/l of ethanol. This was accompanied by the synthesis and accumulation of protein in K. lactis Y-2037 biomass up to 27.5 % and in K. marxianus Y-2042 biomass up to 32.3 % in terms of dry matter. Manganese ions at concentrations of 10 and 25 mg/l had no effect on lactose processing, while manganese ions concentrations of 50 mg/l reduced it. The protein content in the biomass increased to 37.3–43.2 % when we added 10 mg/l of manganese ions, and further to 54.6–55.8 % when we added 50 mg/l. Strain Y-2042 was more sensitive to the effects of manganese ions. Yeast cells released about 10–15 % of the protein into the culture medium. Fermentation was accompanied by the manganese capture by cells and its accumulation in biomass from 12.1–13.1 μg/g if we added 10 mg/l, to 65.8–69.3 μg/g if we added 50 mg/l. The results of this research confirm the possibility and specify the technological conditions for the use of manganese ions to obtain biomass with a high protein and manganese content while maintaining the lactose processing due to fermentation of cheese whey by Kluyveromyces yeast.

  • Open Access

    Immunohistochemical Analysis of TGF-β1 Expression in Rat Kidneys Using a Model of Hydrogen Sulfide and Cyclosporine A Exposure

    by E. V. Trizno, M. N. Trizno, V. V. Novochadov, Е. В. Тризно, М. Н. Тризно, В. В. Новочадов

    Pathological aging of the kidneys is characterized by cellular senescence, inflammation, and fibrosis. The main regulator in this process is TGF-β1, which is secreted as part of the senescence-associated secretory phenotype (SASP). We have modeled accelerated aging using H2S and CsA, which induce oxidative stress. The aim of the study was to evaluate the effect of H₂S and CsA, both individually and in combination, on the expression of TGFβ1 and the development of senescent changes in the kidneys of aged laboratory rats. Materials and methods S . The study was conducted on 44 male white rats older than 18 months in 4 groups: control, H2 (0.26 mmol/day, 10 days), CsA (20 mg/kg/day, 25 days), and H2S+CsA. The kidney paraffin sections were analyzed morphologically and immunohistochemically (QuPath TGFβ1positive cell percentage). Statistical analysis: Kruskal–Wallis test. Results . The highest percentage of TGF-β1positive cells was found in the combined exposure group: up to 7.86 [7,64; 8,03] % in the tubules and up to 7.77 [7,61; 7,95] % in the interstitium. In the isolated exposure to H2S and CsA, the percentage of TGF-β1-positive cells was less: 4.97 [4,68; 5,66] % и 5.71 [5,47; 5,81] % in the tubules, respectively. Conclusion . The combined effect of H₂S and CsA synergistically increases the proportion of TGF-β1-positive cells in the tubules and interstitium of the kidneys, promoting senescence and fibrotic remodeling. TGF-β1 acts as a key marker and driver of pathological kidney aging.

  • Open Access

    Antitumor Activity of New Methylpyrazolotriazine and Pyrazolobenzotriazine Derivatives Tested on MCF-7, MDA-MB-231, and BT-474 Breast Cancer Cell Lines

    by Ахмед Хумаири, Валерий Валерьевич Новочадов, Надежда Викторовна Чердынцева, Владимир Васильевич Удут

    Введение. Рак молочной железы (РМЖ) занимает лидирующие позиции среди онкологических заболеваний по частоте заболеваемости и смертности у женщин во всем мире. Из-за высокой гетерогенности опухолевых клеток и морфофункциональных вариаций подбор эффективных схем лечения часто вызывает затруднения. Ключевыми проблемами при терапии РМЖ является развитие устойчивости к применяемым препаратам, что делает необходимым поиск новых лекарственных средств. Цель. Оценить потенциал двух новых производных метилпиразолотриазина (МПТА 1, МПТА 2) и двух производных пиразолобензотриазина (ПБТА 1, ПБТА 2) на предмет возможности их применения в качестве противоопухолевых средств, в том числе для химиотерапии РМЖ. Материалы и методы. Основной методикой явилось изучение цитотоксической (ЦТА) и цитостатической активности (ЦСА) этих производных в концентрациях от 0,25 до 10,0 мкмоль/л в культурах клеток РМЖ MCF-7, MDA-MB-231 и BT-474, а также нетрансформированных клеток эпителия молочной железы человека MCF-10a. ЦТА определяли методом метилтетразолиевого теста (MTT). Для оценки эффекта рассчитывали IC50T — концентрацию, вызывающую 50 %-ную гибель клеток. ЦСА изучали при более длительной культивации (72 ч), рассчитывая IC50S как концентрацию, тормозящую прирост клеток на 50 %. Статистический анализ проводился с использованием непараметрических тестов (Краскела — Уоллиса и Манна — Уитни) при уровне значимости p < 0,05. Результаты. Наиболее высокая ЦТА в отношении клеток линии MCF-7 выявлена для производного МПТА 1 (IC50 8,15 мкмоль/л), клеток линии MDA-MB-231 — для производного ПБТА3 (IC50 3,79 мкмоль/л), клеток линии BT474 — для производных МПТА 1 (IC50 4,48 мкмоль/л) и МПТА 2 (IC50 6,15 мкмоль/л). Все тестируемые соединения проявили сходную ЦСА в отношении клеток линии MCF-7 в среднем в 1,20–1,45 раза выше активности препарата сравнения Темозоломида (минимальная жизнеспособность клеток — 55 %). В культурах MDA-MB-231 и BT-474 МПТА 1 и МПТА 2 проявляли более высокую ЦСА по сравнению с эффектами ПБТА 1, ПБТА 2 и темозоломида в 1,16–1,50 раза. Все исследованные производные метилпиразолотриазина и пиразолобензотриазина и препарат сравнения Темозоломид продемонстрировали низкую ЦСА в отношении неопухолевых эпителиальных клеток линии MCF-10a; их IC50S лежала за пределами диапазона измерения 10,0 мкмоль/л. Новые производные метилпиразолотриазина и пиразолобензотриазина по возрастанию совокупности ЦТА и ЦСА расположены в порядке: МПТА 2, ПБТА 1 < темозоломид < ПБТА 2 < МПТА 1. Выводы. Таким образом, МПТА 1 (3-(3'-Фенил-4'-метоксикарбонил-изоксазолил)-7-метилпиразоло[5,1-c][1,2,4]триазин) является лидером по ЦТА и ЦСА среди протестированных новых соединений и рекомендуется для дальнейших доклинических испытаний.

  • Open Access

    Analysis of the Antitumor Activity of Four New Phenylpyrazolotriazine Derivatives In Vitro in a Cytotoxicity and Cytostatic Study on Breast Cancer Cell Cultures

    by Ah. H. Al-Humairi, V. V. Novochadov

    Background . The work presents the results of a study of new phenylpyrazolotriazine derivatives in order to establish their potential use as anticancer agents, including for chemotherapy of metastatic breast cancer. The relevance of the work is due to the widespread prevalence of oncological diseases and high breast cancer mortality, which dictate the need for the continuous development of new antitumor drugs. The aim of the study . Screening of the antitumor potential of four new phenylpyrazolotriazine derivatives by testing their cytotoxic (CTA) and cytostatic (CSA) activity on breast cancer cell cultures. Materials and methods . The base methods used in this study are the culturing of MCF-7, MDAMB231, BT474, and MCF-10a cells, as well as determining the CTA and CSA activity of four new phenylpyrazolotriazine derivatives at concentrations from 0.25 to 10.0 mM/L. Results. For the MCF-7 culture, the maximum cell viability inhibition of the comparison drug temozolomide was equal to 2.44 and the concentration causing 50% cell death (IC₅₀) was 6.81 mM/L; for other cultures, CTA indicators were lower. Phenylpyrazolotriazine 3 demonstrated lower activity compared to temozolomide, IC₅₀ was not achieved in most cases. This derivative has been classified as a compound with low CTA and moderate CSA. Phenylpyrazolotriazines 1 and 4 showed higher activity than the comparison drug and were classified as compounds with low or moderate CTA and moderate CSA. Finally, phenylpyrazolotriazine 2 with a maximum cell viability inhibition of 3.70 and IC₅₀ of 1.66 mM/L showed the highest values of CTA and CSA. Conclusion. According to the results of the in vitro study, four new phenylpyrazolotriazine derivatives can be evaluated in ascending order of the CTA and CSA combination: phenylpyrazolotriazine 3 ˂ temozolomide ˂ phenylpyrazolotriazines 1 and 4 ˂ phenylpyrazolotriazine 2. Thus, 3-(3'-Phenyl-4'methoxycarbonyl-isoxazolyl)-7-(p-tolyl)-pyrazolo[5,1-c][1,2,4]triazine (phenylpyrazolotriazine 2) is the undisputed leader in the tested series of new imidazotriazine derivatives and is recommended for further preclinical trials.

  • Open Access

    Bio-conversion of lactose to ethanol by Kluyveromyces lactis yeast as a stage of cheese whey utilization

    by K. S. Abbas, V. V. Novochadov

    Growing accumulation of lactose-containing waste resulting from the growth of cheese production in Russia and throughout the world has increased interest in the search for new effective biotechnologies for their processing, including through the bioconversion of lactose into ethanol. The work used cheese whey with an initial lactose content of 40 g/L and a pH of 4.84, three industrial strains of Kluyveromyces lactis Y-2035, Y-2037, Y-2040, and the reference strain Saccharomyces cerevisae Y-187. We carried out yeast cultivation in a FA-2 fermenter (Prointech, Russia) for 48 hours in cheese whey with the addition of nutrient solutions and zinc ions, at a temperature of 34 °C, stirring, and aeration. As indicators of the dynamics and efficiency of the biotechnological process we choose pH, the number of yeast cells, the concentration of protein, lactose and ethanol in the culture medium for periodical control using commercial kits. After that, we calculated the growth rate, percentage and average rate of lactose utilization, average rate of ethanol formation, and fermentation efficiency. As a result, it was shown that the K. lactis Y-2035, K. lactis Y-2037 and K. lactis Y-2040 can utilize from 76.3 to 86.0 % lactose, while from 17.7 to 21.0 g/l of ethanol is formed in the medium. The fermentation efficiency varies in K. lactis strains from 75.6 to 89.7 % versus 5.6 % in the reference strain S. Cerevisiae Y-187. Among those studied the K. lactis Y-2037 strain has the maximum capacity for lactose utilization and ethanol formation. It is proposed to use technology for processing lactose-containing dairy industry waste by converting lactose into ethanol with yeast cultures K. lactis for obtaining promising raw materials, reducing pollution, as well as for the internal production of bioethanol, and to recommend the K. lactis Y-2037 strain for this purpose.

  • Open Access

    Preclinical studies of cytotoxicity and cytostatic activity of five new imidazotriazine derivatives in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures

    by Ahmed H. Al-Humairi, Mikhail A. Buldakov, Valery V. Novochadov, Nadezhda V. Cherdyntseva, Vladimir V. Udut

    Background. The results of the study of new imidazotriazine derivatives are presented to support their use as antitumor agents, including for breast cancer (BC) chemotherapy. The study is relevant due to the high prevalence and mortality of BC and other socially significant cancers. Antitumor drugs have limitations in their efficacy due to the primary or acquired drug resistance. As a result, 30% to 50% of patients do not receive adequate treatment, determining the need to develop new antitumor drugs. Aim. To evaluate the antitumor potential of 5 new imidazotriazine derivatives by testing their cytotoxic (CTA) and cytostatic (CSA) activity on BC cell cultures. Materials and methods. Culture of MCF-7, MDA-MB231, BT474, and MCF-10a cells and determination of CTA and CSA of imidazotriazine derivatives at concentrations ranging from 0.25 to 10.0 mmol/L. Results. For the MCF-7 culture, the maximum cell survival inhibition by the comparator (temozolomide) was 2.44, and the concentration causing 50% cell death (IC50) was 6.81 mmol/L; for other cell cultures, CTAs were slightly lower. Imidazotriazine 2 and imidazotriazine 3 showed values below or close to temozolomide; IC50 was not achieved in most cases. These two derivatives were considered to have low CTA and moderate CSA. Imidazotriazine 4 and imidazotriazine 5 showed higher activity than the comparator and were considered compounds with moderate CTA and CSA. Finally, imidazotriazine 1 showed the highest CTA and CSA values with a maximum cell survival inhibition of 4.35 and an IC50 of 1.94 mmol/L. Conclusion. Based on the results of the in vitro study, five new imidazotriazine derivatives have CTA and CSA in the following ascending order: imidazotriazine 2, imidazotriazine 3 temozolomide imidazotriazine 4 imidazotriazine 5 imidazotriazine 1. Therefore, 4-aminoimidazo[5,1-c][1,2,4]triazine-3,8-dicarboxylic acid diethyl ether (imidazotriazine 1) is the most promising new imidazotriazine derivative and is recommended for further preclinical studies.

  • Open Access

    Assessment of light chestnut soil phytotoxicity after crude oil pollution and the use of biologics-petrodestructors

    by Denis A. Shevtsov, Elena A. Ivantsova, Valery V. Novochadov

    Light chestnut soil has specific structural organization and chemical composition, suggesting the features of its negative effects on plants (phytotoxicity) in various pollutants, in particular crude oil. The article aimed to consider and discuss results of model experiments with artificial contamination of light chestnut soil with oil and attempts of its purification using modern biological products based on associations of hydrocarbon-oxidizing bacteria (oil degraders). One used infrared spectrometry to determine the content of petroleum products in the soil, and conductometry to measure soil pH. To analyze soil phytotoxicity we used the test system based on germination of Raphanus sativus seeds. It has been shown for Multibac Active and DOP-UNI to remove effectively over 50% of crude oil from soil in 15 days, the higher its initial concentration. This process is accompanied by a decrease in the pH of the soil to 4.55–4.94. Spontaneous utilization of oil is 7.5% at high oil concentrations of in the soil, and it is no more than 4% at low concentrations. Biological products have moderate phytotoxicity, and oil has significant one. Comparing two biologics, we show that Multibac Active has a comparatively higher phytotoxicity, it reduces laboratory germination of seeds by 12%, and DOP-UNI reduced laboratory germination by only 4%. Crude oil reduces germination at a concentration of 2.0 g/kg by 56%, and at a concentration of 4.0 g/kg, it completely suppresses germination of R. sativus seeds. The use of biological products for the purpose of soil purification from oil pollution enhances its phytotoxic properties. These results and findings are of practical importance for the development and optimization of technologies and strategies for bioremediation of soils contaminated with oil and petroleum products.


  • Open Access

    Cytotoxic and cytostatic activity of five new imidazotetrazine derivatives on breast cancer cell cultures MDAMB231, BT474, and MCF-7

    by Ahmed Hamid Al-Humairi, Svetlana E. Sitnikova, Valery V Novochadov

    Introduction: The work presents the results of the study of new imidazotetrazine derivatives to establish the possibility of using them as anticancer agents, including for chemotherapy of metastatic breast cancer. The relevance of the work is due to the wide spread of oncological diseases and high cancer mortality, which dictates the need to constantly obtain cell lines and improve cultivation protocols for testing new antitumor drugs. The goal of this study is to check the potential of five new imidazotetrazine derivatives to become new antitumor drugs, in the scope of studying their cytotoxic and cytostatic activities on breast cancer cell cultures. Materials and Methods: The culturing MCF-7, MDAMB231, BT474, and MCF-10a cells with determining cytotoxic and cytostatic activities of five new azolotetrazine derivatives are base methods used in this study. Results: For the MCF-7 culture, MCS of comparison drug temozolomide was equal to 2.44 and IC50 was 6.81 mM/L; for other cultures CTA indicators were worse. Imidazotetrazine 2 and imidazotetrazine 3 demonstrated CTA indicators lower than those of temozolomide. IC50 was not achieved, and the MCS value varied between 1.34 and 1.74. These two derivatives were classified as the compounds with an extremely low CTA. Imidazotetrazine 1 and iminothiotriazine 5 showed cytotoxic activity higher than that of the comparison drug and we classified these compounds as the ones with a moderate CTA. Finally, we found imidazotetrazine 4 with IC50 of 0.85 mM/L and CTA of 7.34 as a compound with a potentially strong anticancer effect for further investigation. The cytostatic activity of four of the five azoloazine derivatives studied was in a narrow range corresponding to the survival rate from 0.21 to 0.32, depending on the compound and cell culture. Against this background, imidazotetrazine 4 demonstrated a higher CSA, determined by the survival rate from 0.17 to 0.20. Conclusion: As a result of an in vitro study, we found that five new azolotriazine derivatives can be evaluated in the ascending order of these properties, as a combination of CTA+CSA in order imidazotetrazine 2, imidazotetrazine 3 < temozolomide < imidazotetrazine 1, iminothiotriazine 5 < imidazotetrazine 4, although the CSA of all the studied compounds turned out to be high. Thus, 3-Cyclohexyl-4-oxoimidazo[5,1-d]-[1,2,3,5]tetrazine-8-N-piperidinyl-carboxamide (imidazotetrazine 4) is an unconditional leader in the tested series of new azoloazine derivatives and we recommend it for further preclinical trials.


  • Open Access

    Spatial distribution proteoglycans articular cartilage of femoral condyles and tibial plateau in experimental osteoarthritis in rats

    by Pavel A. Krylov, Irina M. Romanova, Ekaterina D. Velikanova, Polina A. Zybinskaya, Aliya A. Abdulova, Valery L. Zagrebin, Valery V. Novochadov, Крылов Павел Андреевич, Романова Ирина Михайловна, Великанова Екатерина Дмитриевна, et al.

    Currently, worldwide research is being conducted on the development of new drugs for viscosupplementation therapy. However, there are a very few studies dedicated to the spatial distribution of proteoglycans in articular cartilage after the use of these drugs. Pulmonary surfactant proteins, which have lubricative functions similar to those of articular cartilage proteoglycans, are possible promising substances for viscosupplementation therapy. The aim of this study is to investigate the effect of a mixture of allogenic surfactant proteins (MASP) on the spatial distribution of proteoglycans and the expression of IL-1 in articular cartilage after their intra-articular injection. Morphological and immunohistochemical studies were conducted using antibodies to aggrecan and lubricin to assess the spatial distribution of proteoglycans, and antibodies to IL-1 were used to identify potential pro-inflammatory processes. Three weeks after intra-articular injection of MASP, the thickness of the articular cartilage and the relief of the joint surface did not change compared to intact rats. However, a decrease in the number of immunopositive chondrocytes to aggrecan in the intermediate zone of the articular cartilage and an increase in IL-1 were observed after MASP injection. The obtained data during the study can be used for further research on MASP in the conditions of experimental osteoarthritis.


  • Open Access

    Antitumor activity of three new azoloazine derivatives in orthotopic transplantation model of human breast cancer cells into mice

    by A. H. Al-Humairi, Д. Л. Сперанский, V. V. Novochadov, S. V. Poroisky, N. V. Cherdyntseva, V. V. Udut

    Breast cancer (BC) is one of the most common types of malignant tumors, which makes scientific research in this area extremely relevant. The difficulties of breast cancer chemotherapy stimulate the search for new drugs to treat this nosology. Derivatives of imidazotriazine and imidazotetrazine, which are analogues of the antitumor drug temozolamide, can be ones of the promising drugs in this regard.The aim of the work was to evaluate the antitumor activity of three new azoloazine derivatives in a xenogeneic breast cancer model in mice in vivo.Materials and methods. A study was conducted on a xenogeneic model of BC. After the immunosuppression with azathioprine, 48 white BALB/c mice were injected with MCF-7 cells, test derivatives, and the reference drug epirubicin at doses of 1/2 IC50 and 1/10 IC50, into the base of the mammary gland once. The body weight of the mice was monitored; on the 15th day, at the end of the experiment, the relative volume was assessed.Results and discussion. Among the three compounds studied, imidazotetrazine 1 showed the most encouraging results: stopping the loss of body weight in the mice caused by the administration of tumor cells, and reducing the tumor volume on the 15th day of the experiment to 50.6% of that in the control when using a dose of 1/10 IC50, up to 39.2% – when using a dose of 1/2 IC50, which significantly exceeded the values of the reference drug epirubicin and the values in the control group. In the histological examination, the signs of spread and preservation of tumor cells viability of the MCF-7 line after its administration were minimal, the value of the histological malignancy index decreased by 9.3% of the control value.Conclusion. Among the tested azoloazine derivatives, 3-cyclohexyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-N-piperidinylcarboxamide is the undisputed leader, causing inhibition of the tumor growth in a xenogeneic model in vivo.